H. Lundbeck, Takeda in neurology deal

H. Lundbeck (CSE:LUN) and Takeda (Tokyo:4502) partnered to develop and commercialize two bisarylsulphanylamines from LUN in the U.S. and Japan to treat mood and anxiety disorders. Lu AA21004, a serotonin modulator and stimulator, is in Phase II testing to treat major depressive disorder (MDD), and Lu AA24530 is an undisclosed compound that is in Phase I testing for depression. Takeda also received an option to two other LUN bisarylsulphanylamines: Lu AA34893, which is in Phase I testing for depression, and an undisclosed preclinical compound. ...